Kornimate/medical-research-clean huggingface dataset:
gut microbiome in people living with hiv and hbv

Conditions: Human Immunodeficiency Virus; Chronic Hepatitis b; Gut Microbiome

Summary: building a microbiome data platform and conducting clinical evidence research in individuals infected with the human immunodeficiency virus (hiv) and hepatitis b virus.

chronic hiv infection, which often results in metabolic disorders, leads to shifts in the gut microbiota, contributing to immune activation and chronic inflammation. this study seeks to compare the gut microbiota in individuals with chronic hiv infection and chronic hepatitis b patients. the objective is to identify specific gut bacterial strains and metabolic pathways linked to the metabolic disorders commonly observed in hiv patients.

Eligibility criteria:
inclusion criteria: 1. hiv patients * inidividuals over 19 years old * hiv patients on antiretroviral therapy (art) 2. hbv patients * individuals over 19 years old * chronic hepatitis b patients with either chronic hepatitis, liver cirrhosis or hepatocellular carcinoma exclusion criteria: 1. patients with indeterminate colitis 2. individuals who have used antibiotics or steroids within 24 hours of the microbiome sample collection (excluding antiviral treatments for hepatitis b and hiv) 3. individuals who have used vaginal or external medications, including antifungal agents, within 24 hours of microbiome sample collection 4. those with acute illnesses, with or without fever, of moderate or severe severity; however, sampling may be postponed until the subject recovers. 5. individuals with gastrointestinal disorders that may impact microbiome analysis and are currently medically uncontrolled or under treatment for the respective condition 6. individuals with a positive result in a urine pregnancy test, pregnant, or breastfeeding at the time of microbiome sample collection 7. individuals for whom medical opinions suspect that they may have an impact on the sample collection at the time of microbiome collection.
impact of oct imaging on decision making during pci in acs patients

Conditions: Acute Coronary Syndrome

Summary: optical coherence tomography (oct) provides valuable information to guide percutaneous coronary intervention (pci) in acute coronary syndrome (acs) regarding lesion preparation, stent sizing, and stent optimization.

oct can be used in acute coronary syndrome (acs). acs has more complex culprit lesion morphologies and larger extent of coronary atherosclerosis compared with stable coronary artery disease. the detailed vascular information obtained by oct may impact pci in acs, and which may improve acute results and late outcomes of pci. stent expansion immediately after pci is a strong predictor of late outcomes of pci, and it is associated with late clinical outcomes in many previous trials.

Eligibility criteria:
inclusion criteria: * patients presented with acute coronary syndrome. * pci was done to them with stent implantation. exclusion criteria: * multivessel pci at the index procedure. * patients with acs due to graft failure post cabg. * patients treated with no stent implantation.

Keywords: oct, stent implantation
improving neuroprotective strategy for ischemic stroke with sufficient recanalization after thrombectomy by edaravone dexborneol

Conditions: Stroke; Endovascular Thrombectomy

Summary: to explore the safety and efficacy of edaravone dexborneol for the treatment of acute ischemic stroke patients who received endovascular thrombectomy.


Eligibility criteria:
inclusion criteria: 1. 18 to 80 years of age; 2. patients who presented with acute ischemic stroke and a large vessel occlusion in the anterior circulation and met the criteria of mechanical thrombectomy; 3. sufficient recanalization within 9 hours of stroke onset; 4. sufficient recanalization （tici 2b-3）; 5. acute ischemic stroke with neurological baseline deficit equivalent to the national institute of health stroke scale (nihss) ≥ 6 before recanalization treatment; 6. first ever stroke or mrs≤1 after previous disease 7. the availability of informed consent. exclusion criteria: 1. acute ischemic stroke patients with insufficient recanalization（tici \< 2a） 2. hemorrhagic transformation (ph2) indicated by ncct performed after the operation immediately; 3. hemorrhagic stroke: cerebral hemorrhage, subarachnoid hemorrhage; 4. coagulation disorders, systematic hemorrhagic tendency, thrombocytopenia （ \<100000/mm3）; 5. severe hepatic or renal dysfunction, increase in alt or ast (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis; 6. severe hypertension (systolic blood pressure over 200mmhg or diastolic blood pressure over 110 mmhg); 7. patients with malignant tumor or under antineoplastic therapy with estimated lifetime less than 3 months; 8. pregnancy, plan to get pregnant or during lactation; 9. patients with contraindication or allergic to any ingredient of drugs in our study; 10. unsuitable for this clinical studies assessed by researcher.
comparative impact of protocolized management, intensive rehabilitation versus long-term classic rehabilitation of dyslexic children.

Conditions: Dyslexia; Speech Therapy; Children, Only

Summary: dyslexia is characterized by difficulties with accurate and/or fluent word recognition and by poor spelling and decoding abilities. in france, dyslexia is a public health disorder. dyslexia is a real public health problem in france, affecting 6% of the general population. however, no clinical trial of a standardized rehabilitation has shown an impact on reading fluency. in the era of intensive rehabilitation, a new protocol based on the current data from the medical literature has been designed.


Eligibility criteria:
inclusion criteria: * children from 8 to 12 years old, * living in and around 50 kilometers from besançon. * diagnosis of dyslexia according to the dsm-v or cim-10 requirements. * consent form signed by the parental authority and the child, * affiliation to a social security system. exclusion criteria: * mother's medical history of pregnancy or delivery complications, * patients's medical history of neurological infectious, vascular or tumoral events, * patient's medical history of intellectual deficiency, * patients's medical history of visual or hearing disorders, * patient's medical history of psychiatric disorders (especially diagnosis of attention deficit / hyperactivity disorders (ad/hd)), * legal incapacity, * limited cooperation suspected by the investigator.

Keywords: dyslexia speech therapy children intensive rehabilitation
frequency analysis of coronary artery disease

Conditions: Coronary Artery Disease

Summary: the purpose of this study is to determine if coronary artery disease can be detected using an electronic, acoustic recording instrument. the presence or absence of abnormal pathology will be confirmed by diagnostic angiography as part of the normal patient care at this institution.


Eligibility criteria:
inclusion criteria: * patients aged 18-89 years old and recommended for a cardiology related angiogram within 24 hours exclusion criteria: * any patient less than 18 years of age or greater than 89 years of age. * any patient with any of the following conditions: pregnant or nursing, prior myocardial infarction, left ventricular device, heart transplant, valve replacement, congestive heart failure, atrial fibrillation (non-intermittent), endocarditis or any heart viral or bacterial infection, any patient who has or requires medication or other heart rhythm altering treatment.

Keywords: acoustic digital sound vibration coronary auscultation artery diagnosis
recovery from acute immune failure in septic shock by immune cell extracorporeal therapy - observational long-term outcome follow up

Conditions: Severe Sepsis

Summary: subjects previously enrolled / randomized in the reactif-ice (recovery from acute immune failure in septic shock by immune cell extracorporeal terapy - immune competence enhancement) study received either standard sepsis treatment (control group) or standard sepsis treatment and additionally the artice treatment (treatment group) during their index hospitalization. all subjects are followed up for 90 days after enrollment. in this long term follow up study, the enrolled subjects shall be followed up beyond 90 days for up to 5 years.

sepsis is a worldwide health threat because of high mortality and the development of long-lasting disabilities, including physical and cognitive impairment and mental disorders, known collectively as post-intensive care syndrome (pics), which contribute to reduced health-related quality of life (hrqol) for several years even after successful recovery from the initial acute sepsis state. sepsis survivors often need a longer period of rehabilitation, consuming more medical and social resources and struggle with financial burdens. in the reactif-ice study, that started enrolling patients in july 2022, up to 142 subjects with severe sepsis are to be enrolled and randomized into a therapy group (receiving the artice treatment (extracorporeal immune cell plasma perfusion) on top of standard care) and control group (standard care only). these subjects were followed up according the reactif-ice study protocol for 90 days. since there is still a large need for long-term outcome data of sepsis patients, collecting data of the reactif-ice patients over a longer period of time would provide important additional information regarding: 1. general long term clinical and socio-economic outcome of sepsis survivors 2. long-term outcome details of the reactif-ice patient population 3. the potential long-term medical outcome effects of the additional artice treatment compared to standard treatment alone. 4. the potential long-term health-related quality-of-life effects of reactif-ice patient population 5. the potential long-term health-related quality-of-life effects of the additional artice treatment compared to standard treatment alone. in this long term follow up study, the enrolled subjects shall be followed up beyond 90 days for up to 5 years.

Eligibility criteria:
inclusion criteria: 1. subject or legal surrogate is willing and able to provide written informed consent and comply with all protocol requirements or the implementation of other established procedures according to the local regulations of the contributing center to include subjects who are unable to provide informed consent. 2. subject was enrolled in the reactif-ice study and successfully passed the day 2 re-evaluation of that trial. exclusion criteria: * none
tension band wiring versus cannulated screws in fixation of medial malleolus in ankle fracture

Conditions: Medial Malleolus Fracture

Summary: this is a prospective randomized study conducted on 30 patients with an age spanning between 20 and 55 years. half of the sample was treated by tension band wiring for closed medial malleolar fractures, and the other half by two cannulated screws. the patients were assessed at (6w-3months and 6months) for clinical and radiological union and evaluated functionally (12 months) using modified olerund and molander scoring system.


Eligibility criteria:
inclusion criteria: 1. patients aged from 20-55 years. 2. isolated or bimalleolar ankle fractures. 3. closed fractures. exclusion criteria: 1. patient with poor bone quality on x ray (radiological osteopenia, thinning of the cortices, loss of trabecular definitions and previous insufficiency fractures) 2. type d isolated medial malleolus, supination adduction (vertical malleolar) fractures. 3. comminuted fractures. 4. skeletally immature patients.

Keywords: fixation of medial malleolus tension band malleolus fracture ankle fracture
effect of lidocaine sprayed on hemodynamics during endotracheal intubation

Conditions: Neurosurgical Patients

Summary: a previous study demonstrated topical lidocaine spray on the larynx and the trachea is effective in reducing hemodynamic response to laryngoscopy and endotracheal intubation. in clinical practice, blind oropharyngeal application of lidocaine without aiding direct laryngoscopy can not assured that sprayed lidocaine effectively reaches the larynx and trachea. therefore, direct laryngoscopy should be necessary to reach topical lidocaine to correct sites. unfortunately, direct laryngoscopy itself can affect hemodynamics during spraying lidocaine. in this study, we will investigate an effect of lidocaine sprayed on direct laryngoscopy and the tracheal mucosa on hemodynamic change throughout intubation.


Eligibility criteria:
inclusion criteria: * aged 20-60 years, * asa groups i or ii exclusion criteria: * asa iii or iv, * hypertension, * anticipated difficult airway, and * severe coronary and cerebrovascular diseases
effect of bladder distension on dosimetry in brachytherapy of cervical cancer

Conditions: Cervical Cancer

Summary: the purpose of this study is to compare, for each patient, dosimetry of organs at risk (bladder, rectum, sigmoid, small bowel) in two bladder distension procedures (emptied by a urinary catheter or filled with 120cc) during pdr 3d image-guided brachytherapy of cervical cancer.


Eligibility criteria:
inclusion criteria: * age \> or = 18 years old * with a cervical cancer histologically proven (squamous cell carcinoma, adenocarcinoma and neuroendocrine cell carcinoma) * utero-vaginal brachytherapy indications:: * stage 1b1: brachytherapy before surgery * stages ib2 to iiib: after pelvic radiotherapy (45gy/25 fractions/5 weeks) with or without concomitant chemotherapy * ability to provide an informed written consent form * patient must be affiliated to a social security system exclusion criteria: * age \< 18 years old * history of pelvic radiotherapy * history of pelvic surgery * recent joint prothesis (\<3 months) * pregnant woman or being breastfeeding * patients deprived of liberty or under supervision

Keywords: brachytherapy organs at risk bladder volume cervical cancer
influence of prenatal and early childhood home-visiting by nurses on development of chronic disease

Conditions: Chronic Disease

Summary: this study is a longitudinal cohort study that follows participants in a randomized clinical trial of a program of prenatal and early child home visiting on maternal and offspring risks for chronic disease.

addressing the unacceptably high rates of chronic disease and premature mortality among low-income african americans (aa) is a public health imperative. the proposed study addresses this challenge by building upon decades of follow-up of low-income, primarily aa participants in a randomized clinical trial of the nurse-family partnership (nfp), a program of prenatal and infant/toddler nurse home visiting for low-income mothers with no previous live births. it examines nfp effects on risks for cardiovascular disease (cvd), type 2 diabetes (t2d), and chronic kidney disease (ckd), as well as premature mortality among both mothers and their first-born offspring at offspring age 30. it is the first adequately powered study of a very early intervention to examine risks for chronic disease and mortality, assessing both mothers and their first-born offspring. please note that for this section of the longitudinal study, just the outcome measures for 30 years after delivery are being measured. the study team also measured these outcome measures at baselines, 12 years, and 18 years after delivery in other studies, but for this specific study, the time frame for the listed outcome measures is 30 years after delivery.

Eligibility criteria:
inclusion criteria: * mothers who participated in a randomized clinical trial of nurse home visiting and their first-born offspring. * women \ no previous live births * no specific chronic illnesses thought to contribute to fetal growth retardation or preterm delivery * at least two of the following sociodemographic risk conditions: unmarried, less than 12 years of education, and unemployed exclusion criteria: * participants who refused assessments at earlier phases of data gathering. * women \> 29 weeks pregnant * previous live births * possessing chronic illnesses like hypertensive disorders requiring medical treatment, severe cardiac disease, large uterine fibroids.
staccato loxapine pulmonary safety in patients with copd

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the purpose of this study is to assess the pulmonary safety of 2 doses of staccato loxapine within a day in patients with copd.

to address the possibility that inhalation of loxapine may have adverse pulmonary effects, we studied two 10-mg inhaled doses of loxapine or placebo were given 10 hr apart to subjects with chronic obstructive pulmonary disease (copd). the objective was to determine the time course and reversibility of pulmonary effects for inhaled loxapine compared with placebo.

Eligibility criteria:
inclusion criteria: * history of copd for at least 6 months with pre-bronchodilator fev1 ≥40% of predicted value and \>15 pack-year history of cigarette smoking. exclusion criteria: * history of asthma, or any other acute or chronic pulmonary disease.

Keywords: staccato loxapine copd pulmonary safety
ultrasound assessment of dilapan-s

Conditions: Cervical Dilation; Induction of Labor; Ultrasound Evaluation

Summary: the goal of this observational prospective study is to assess the change in dilapan-s rod diameters using transvaginal ultrasound over a period of 12 hours in term women undergoing induction of labor.

on admission for induction, study participants assigned to each group underwent continuous cardiotocography for 20 minutes prior to placement of the dilapan-s rods (rod size: 4 x 65mm). placement of the dilapan-s rods was limited to three physicians with the majority placed by the primary investigator. placement was completed in a sterile manner under direct visualization and in accordance with the manufacturer's guidelines. the number of rods placed varied per individual and was based on the discretion of the physician. each participant allocated to the dilapan-s with saturated gauze group received placement of one, 4x4 inch gauze saturated with 10 cc of normal saline and placed at the level of the external os. immediately after placement of the dilapan-s rods, the study participant was asked to complete a patient satisfaction survey. pre-specified transvaginal ultrasound assessment was performed at hours 3, 6, 8, and 12 post dilapan-s placement using a ge voluson e10 machine with a transvaginal ge ric 5-9d transducer. performance of the ultrasound evaluation was limited to the primary investigator and two co-authors of the study. after completion of the 12-hour ultrasound, the dilapan-s rods and gauze, if used, were removed as per the manufacturer's instructions. the participant was then asked to complete a post dilapan-s patient satisfaction survey.

Eligibility criteria:
inclusion criteria: * pregnant individuals at gestational age 37 weeks or greater. * scheduled medical or elective induction at sentara norfolk general hospital. * live, singleton iup. * vertex presentation. * intact membranes. * bishop score of 6 or less. exclusion criteria: * unwilling or unable to provide consent. * intrauterine fetal demise * contraindications to vaginal delivery. * bmi \> 45 * vaginal bleeding * clinically evident genital tract infection
analgesic efficacy and safety of valdecoxib for treatment of post-surgical pain from bunionectomy surgery

Conditions: Pain; Hallux Valgus

Summary: the study was done to evaluate the pain relief and safety of 2 valdecoxib doses compared to placebo in patients with moderate or severe pain following bunionectomy surgery, and to evaluate the effect of the 2 valdecoxib doses compared to placebo on health outcome measures and on the occurrence of opioid related symptoms.


Eligibility criteria:
inclusion criteria: * patients who underwent an uncomplicated primary unilateral first metatarsal bunionectomy surgery (with or without ipsilateral hammer toe repair) who required open manipulation of bone with periosteal evaluation under general anesthesia (mayo block) * patients with a baseline pain intensity (vas) of greater than or equal to 45 mm * patients with a baseline pain intensity (categorical) of moderate or severe exclusion criteria: * patients scheduled to undergo other surgical procedures that would be expected to produce a greater degree of surgical trauma than the orthopedic procedure alone * treatment with patient-controlled analgesia (pca) subsequent to the end of anesthesia * long-acting local anesthetics or local anesthetics coadministered with epinephrine injected into the index joint space * use of tricyclic antidepressants, tranquilizers, neuroleptics, neuroleptic antiemetics, cox-2 inhibitors, nsaids, and corticosteroids * use of nsaid or analgesia after midnight the night prior to surgery or unwilling to abstain from nsaids or other analgesics, except as specified in the protocol, during the study
electronic patient reported symptom assessment

Conditions: Gynecologic Cancer; Breast Cancer; Thoracic Cancer; Gastrointestinal Cancer

Summary: the purpose of this study is to assess whether using computerized screening questions can improve how well we manage symptoms related to cancer and cancer treatments. advance care planning is a process in which teams of experts assist in with treatment plans, managing pain and other symptoms, emotional issues, and end of life issues. with advances in technology, it is now possible to get the patient's feedback directly and more often. it is thought that repeated questionnaires completed by the patient will provide a better and more accurate measure of the patient's needs and experiences but this has not been tested. this study is designed to learn if using a computerized assessment repeatedly is better than standard planning techniques.


Eligibility criteria:
inclusion criteria: 1. women who have a diagnosis of metastatic breast, gynecologic, thoracic, or gastrointestinal malignancy. women diagnosed with non-solid organ tumors (i.e., lymphoma, leukemia) will be excluded as their symptom profile in advanced/metastatic disease is dissimilar. 2. reason for admission must be for symptom management from cancer or cancer therapy. 3. patients must be age 18 or older. 4. only patients cared for at the robert h. lurie comprehensive cancer center (rhlccc) will be eligible for this small pilot study. 5. patients must not be enrolled in hospice care. 6. patients must have a performance status 0-3 (ecog scale). 7. patients must be alert and oriented to time, place, and person. must be able to answer questions. 8. patients must be able to speak, read, and communicate in english. 9. patients must have a signed consent and authorization for research and be amenable to be followed for outcomes/response throughout and after hospitalization. exclusion criteria: -

Keywords: advanced care planning palliative care women